Glaukos announced that it has submitted a supplemental pre-market approval (PMA) application to the FDA for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is an investigational device designed for use in a standalone procedure to reduce elevated IOP in patients with open-angle glaucoma uncontrolled by prior surgical or medical therapy. It includes three heparin-coated titanium stents preloaded into an auto-injection system that allows the …
Sleeping Off Diabetic Retinopathy
Sharing results from a real-world single center study of patients with diabetic macular oedema (DMO) who wore a home-use sleep mask (Noctura 400) for 12 months PolyPhotonix, the manufacturer of the Noctura 400 – a treatment for diabetic retinopathy – recently completed a realworld study at an NHS hospital in the UK, which began in 2019. The study analyzed the …
AI-supported test can predict eye disease that leads to blindness
In a clinical trial of 113 patients led by researchers at Imperial College London and UCL, retinal imaging technology called Detection of Apoptosis in Retinal Cells (DARC) was able to identify areas of the eye that were showing signs of geographic atrophy (GA) – a common condition that causes reduced vision and blindness.The researchers believe that this technology could be …
iStent inject safe, efficacious in open-angle glaucoma
The iStent inject was safe and effective for treating multiple types of primary open-angle glaucoma individually and in conjunction with cataract surgery, according to data published in Journal of Cataract and Refractive Surgery.
Cataract surgery lowers IOP, medication use
Patients with ocular hypertension may benefit from cataract surgery, according to findings published in the American Journal of Ophthalmology.“Studies suggest that cataract surgery lowers IOP, and that this reduction is generally proportional to presurgical IOP. As well, several papers report a decrease in ocular hypotensive medications with cataract surgery,” Steven L. Mansberger, MD, MPH, ophthalmologist at Legacy Health in Portland, …
Dry eye disease cream demonstrates improvement, rapid onset of action in phase 2 trial
AXR-270 demonstrated ‘statically and clinically meaningful improvement’ in patients with dry eye disease associated with meibomian gland dysfunction, according to a press release from AxeroVision.
